Applied Molecular Transport to Present at SVB Leerink Virtual 11th Annual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2022 - Applied Molecular Transport Inc. (Nasdaq: AMTI) announced that CEO Tahir Mahmood, Ph.D., will participate in a fireside chat at the SVB Leerink Virtual 11th Annual Global Healthcare Conference on February 17, 2022, at 1:00 p.m. ET. A live webcast will be available on the company’s Events page, with an archived replay for 30 days post-event. AMT specializes in developing novel oral biologics targeting autoimmune and inflammatory diseases, leveraging its proprietary technology platform for efficient drug delivery.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder, will participate in a fireside chat during the SVB Leerink Virtual 11th Annual Global Healthcare Conference on Thursday, February 17, 2022 at 1:00 p.m. ET.
A live webcast will be accessible via the Events page of the Applied Molecular Transport website at https://ir.appliedmt.com/news-events/events. An archived replay will be available for 30 days following the event.
About Applied Molecular Transport Inc.
Applied Molecular Transport Inc. is a clinical-stage biopharmaceutical company leveraging its proprietary technology platform to design and develop a pipeline of novel oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. AMT’s proprietary technology platform allows it to exploit existing natural cellular trafficking pathways to facilitate the active transport of diverse therapeutic modalities across the intestinal epithelial (IE) barrier. Active transport is an efficient mechanism that uses the cell’s own machinery to transport materials across the IE barrier. AMT believes that its ability to exploit this mechanism is a key differentiator of its approach. AMT is developing additional oral biologic product candidates in patient-friendly oral forms that are designed to either target local intestinal tissue or enter systemic circulation to precisely address the relevant pathophysiology of disease.
AMT’s headquarters, internal GMP manufacturing and lab facilities are located in South San Francisco, CA. For additional information on AMT, please visit www.appliedmt.com.
Investor Relations Contact:
Andrew Chang
Head, Investor Relations & Corporate Communications
achang@appliedmt.com
Media Contacts:
Alexandra Santos
Wheelhouse Life Science Advisors
asantos@wheelhouselsa.com
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
FAQ
What event will AMTI's CEO participate in on February 17, 2022?
What is the purpose of the fireside chat for AMTI?
How can I access the live webcast of AMTI's event?
What does Applied Molecular Transport Inc. specialize in?
How long will the replay of AMTI's fireside chat be available?
